OBJECTIVE: Fatigue is a common, disabling symptom of multiple sclerosis (MS), but little is known about fatigue in patients with clinically isolated syndrome (CIS), often the presenting symptom of MS. We aimed to investigate the prevalence and severity of fatigue in patients with CIS, and its association with a diagnosis of clinically definite MS (CDMS). METHODS: 127 patients were consecutively included in our ongoing prospective CIS study. At baseline, clinical, demographic, laboratory and MRI data were collected, and fatigue severity was assessed using Krupp's Fatigue Severity Scale (FSS); fatigue was defined as FSS≥5.0. Fatigue scores were compared with scores of 113 healthy controls and with scores from the literature. The association of fatigue with CDMS was calculated using Cox regression models. RESULTS: The mean FSS of patients with CIS was 4.3, similar to MS patients, and significantly higher than that of healthy individuals (p<0.001). Fatigue prevalence in patients with CIS (46.5%) was significantly higher than in controls (p<0.001). Fifty-two patients (40.9%) reached CDMS during follow-up. Fatigue was associated with a diagnosis of CDMS in univariate analysis (HR 2.6, 95% CI 1.5 to 4.6) and in multivariate analysis correcting for sex, age, neuroanatomical localisation of CIS, 25-OH-vitamin D, anxiety, depression, MRI dissemination in space and gadolinium enhancement (HR 4.5, 95% CI 1.9 to 10.6). CONCLUSIONS: Already at the stage of CIS, fatigue is a very common symptom, with a severity similar to fatigue in MS patients. This fatigue seems unrelated to the type or severity of the attack. Importantly, we found that fatigue was an independent predictor of a subsequent diagnosis of MS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE:Fatigue is a common, disabling symptom of multiple sclerosis (MS), but little is known about fatigue in patients with clinically isolated syndrome (CIS), often the presenting symptom of MS. We aimed to investigate the prevalence and severity of fatigue in patients with CIS, and its association with a diagnosis of clinically definite MS (CDMS). METHODS: 127 patients were consecutively included in our ongoing prospective CIS study. At baseline, clinical, demographic, laboratory and MRI data were collected, and fatigue severity was assessed using Krupp's Fatigue Severity Scale (FSS); fatigue was defined as FSS≥5.0. Fatigue scores were compared with scores of 113 healthy controls and with scores from the literature. The association of fatigue with CDMS was calculated using Cox regression models. RESULTS: The mean FSS of patients with CIS was 4.3, similar to MSpatients, and significantly higher than that of healthy individuals (p<0.001). Fatigue prevalence in patients with CIS (46.5%) was significantly higher than in controls (p<0.001). Fifty-two patients (40.9%) reached CDMS during follow-up. Fatigue was associated with a diagnosis of CDMS in univariate analysis (HR 2.6, 95% CI 1.5 to 4.6) and in multivariate analysis correcting for sex, age, neuroanatomical localisation of CIS, 25-OH-vitamin D, anxiety, depression, MRI dissemination in space and gadolinium enhancement (HR 4.5, 95% CI 1.9 to 10.6). CONCLUSIONS: Already at the stage of CIS, fatigue is a very common symptom, with a severity similar to fatigue in MSpatients. This fatigue seems unrelated to the type or severity of the attack. Importantly, we found that fatigue was an independent predictor of a subsequent diagnosis of MS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Carina Sander; Paul Eling; Katrin Hanken; Jan Klein; Andreas Kastrup; Helmut Hildebrandt Journal: Front Neurol Date: 2016-09-21 Impact factor: 4.003
Authors: Eva Hyncicova; Adam Kalina; Martin Vyhnalek; Tomas Nikolai; Lukas Martinkovic; Jiri Lisy; Jakub Hort; Eva Meluzinova; Jan Laczó Journal: PLoS One Date: 2018-07-06 Impact factor: 3.240
Authors: Roos M van der Vuurst de Vries; Jan Ja van den Dorpel; Julia Y Mescheriakova; Tessel F Runia; Naghmeh Jafari; Theodora Am Siepman; Dimitris Rizopoulos; Ewout W Steyerberg; Rogier Q Hintzen Journal: Mult Scler Date: 2017-05-23 Impact factor: 6.312
Authors: Liza Rijvers; Marie-José Melief; Roos M van der Vuurst de Vries; Maeva Stéphant; Jamie van Langelaar; Annet F Wierenga-Wolf; Jeanet M Hogervorst; Anneke J Geurts-Moespot; Fred C G J Sweep; Rogier Q Hintzen; Marvin M van Luijn Journal: Eur J Immunol Date: 2018-09-25 Impact factor: 5.532